Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Direct Oral Anticoagulants Compared with Vitamin K Antagonists for Left Ventricular Thrombus: A Systematic Review and Meta-analysis

Author(s): Shu Fang, Bao-Zhen Zhu, Fan Yang, Zhe Wang, Qian Xiang and Yan-Jun Gong*

Volume 28, Issue 23, 2022

Published on: 13 July, 2022

Page: [1902 - 1910] Pages: 9

DOI: 10.2174/1381612828666220408120832

Price: $65

Abstract

Background: Direct oral anticoagulants (DOACs) are the guideline-recommended therapy for some hypercoagulable diseases but are used off-label for left ventricular thrombus (LVT) owing to a paucity of evidence. We performed a meta-analysis to assess the safety and efficacy of DOACs compared with vitamin K antagonists (VKAs) for LVT treatment.

Methods: We comprehensively searched PubMed, EMBASE, Cochrane Library, and Web of Science databases for studies that compared DOACs with VKAs for LVT treatment. Outcome indicators included stroke or systemic embolism (SSE), thrombus resolution, bleeding, and death. The Newcastle-Ottawa scale was used to evaluate the quality of included studies. Data were analyzed using Review Manager 5.3, and the meta-analysis is registered at PROSPERO (CRD 42020211376).

Results: We included 12 observational studies (n = 2262 patients). SSE was similar for DOACs and VKAs groups (odds ratio (OR) = 1.01, 95% confidence interval (CI) 0.66-1.54, P = 0.95). For thrombus resolution, DOACs were not significantly different to VKAs (OR = 1.15, 95% CI 0.54-2.45, P = 0.71). DOACs and VKAs had a similar bleeding risk (OR = 0.78, 95% CI 0.45-1.35, P = 0.37). DOACs and VKAs groups had a comparable mortality (OR = 0.91, 95% CI 0.50-1.65, P = 0.76). Subgroup analysis showed that post-acute myocardial infarction (AMI) patients using DOACs had a lower risk of SSE (OR = 0.24, 95% CI 0.07-0.87, P = 0.03) and bleeding (OR = 0.38, 95% CI 0.18-0.81, P = 0.01).

Conclusion: DOACs and VKAs showed no difference in the safety and efficacy of patients with LVT. DOACs might be superior to VKAs for LVT treatment in post-AMI patients.

Keywords: Left ventricular thrombus, direct oral anticoagulants, vitamin K antagonists, warfarin, systolic function, ischemic bowel.

« Previous Next »
[1]
McCarthy CP, Vaduganathan M, McCarthy KJ, Januzzi JL Jr, Bhatt DL, McEvoy JW. Left ventricular thrombus after acute myocardial infarction: Screening, prevention, and treatment. JAMA Cardiol 2018; 3(7): 642-9.
[http://dx.doi.org/10.1001/jamacardio.2018.1086] [PMID: 29800958]
[2]
Visser CA, Kan G, Meltzer RS, Dunning AJ, Roelandt J. Embolic potential of left ventricular thrombus after myocardial infarction: A two-dimensional echocardiographic study of 119 patients. J Am Coll Cardiol 1985; 5(6): 1276-80.
[http://dx.doi.org/10.1016/S0735-1097(85)80336-3] [PMID: 3998310]
[3]
Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39(2): 119-77.
[http://dx.doi.org/10.1093/eurheartj/ehx393] [PMID: 28886621]
[4]
Osmancik P, Herman D, Neuzil P, et al. PRAGUE-17 Trial Investigators. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol 2020; 75(25): 3122-35.
[http://dx.doi.org/10.1016/j.jacc.2020.04.067] [PMID: 32586585]
[5]
Patti G, Pecen L, Lucerna M, et al. Net clinical benefit of non-vitamin K antagonist vs vitamin k antagonist anticoagulants in elderly patients with atrial fibrillation. Am J Med 2019; 132(6): 749-757.e5.
[http://dx.doi.org/10.1016/j.amjmed.2018.12.036] [PMID: 30664837]
[6]
Bromley A, Plitt A. A review of the role of non-Vitamin K oral anticoagulants in the acute and long-term treatment of venous thromboembolism. Cardiol Ther 2018; 7(1): 1-13.
[http://dx.doi.org/10.1007/s40119-018-0107-0] [PMID: 29525891]
[7]
Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.
[http://dx.doi.org/10.1056/NEJMoa1009638] [PMID: 21830957]
[8]
Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139-51.
[http://dx.doi.org/10.1056/NEJMoa0905561] [PMID: 19717844]
[9]
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014; 383(9921): 955-62.
[http://dx.doi.org/10.1016/S0140-6736(13)62343-0] [PMID: 24315724]
[10]
Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45(7): 2160-236.
[http://dx.doi.org/10.1161/STR.0000000000000024] [PMID: 24788967]
[11]
Yunis A, Seese L, Stearns B, Genuardi M, Thoma F, Kilic A. Direct oral anticoagulants are effective therapy in treating left ventricular thrombi. J Am Coll Cardiol 2020; 75(11): 948.
[http://dx.doi.org/10.1016/S0735-1097(20)31575-8]
[12]
Robinson A, Ruth B, Dent J. Direct oral anticoagulants compared to warfarin for left ventricular thrombi: A single center experience. J Am Coll Cardiol 2018; 71(11): 981.
[http://dx.doi.org/10.1016/S0735-1097(18)31522-5]
[13]
Gama F, Freitas P, Trabulo M, et al. Direct oral anticoagulants are an effective therapy for left ventricular thrombus formation. Eur Heart J 2019; 40(Supplement_1): ehz747-ehz1018.
[14]
Iqbal H, Straw S, Craven TP, Stirling K, Wheatcroft SB, Witte KK. Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. ESC Heart Fail 2020; 7(5): 2032-41.
[http://dx.doi.org/10.1002/ehf2.12718] [PMID: 32583975]
[15]
Guddeti RR, Anwar M, Walters RW, et al. Treatment of left ventricular thrombus with direct oral anticoagulants: A retrospective observational study. Am J Med 2020; 133(12): 1488-91.
[http://dx.doi.org/10.1016/j.amjmed.2020.05.025] [PMID: 32598904]
[16]
Li X, Ge Z. Comparative study of rivaroxaban and warfarin for treating the patients with left ventricular thrombus. Chinese Circul J 2015; 30: 559-61.
[17]
Jones DA, Wright P, Alizadeh MA, et al. The use of Novel Oal Anti-Coagulant’s (NOAC) compared to vtamin K antagonists (Warfarin) in patients with left ventricular thrombus after Acute Myocardial Infarction (AMI). Eur Heart J Cardiovasc Pharmacother 2021; 7(5): 398-404.
[PMID: 32730627]
[18]
Durrer-Ariyakuddy K, Moccetti F, Stämpfli SF, et al. Direct oral anticoagulans versus vitamin K-antagonists for treatment of left ventricular thrombus-Insights from multicenter registry. Kardiovaskulare Medizin 2019; 22.
[19]
Daher J, Da Costa A, Hilaire C, et al. Management of left ventricular thrombi with direct oral anticoagulants: Retrospective comparative study with vitamin K antagonists. Clin Drug Investig 2020; 40(4): 343-53.
[http://dx.doi.org/10.1007/s40261-020-00898-3] [PMID: 32144651]
[20]
Chao P, Li J, Chen X, Wang Y, Ren P. Incidence of systemic embolism in patients with left ventricular thrombus after myocardial infarction treated with new oral anticoagulants or vitamin K antagonists. Chinese Circul J 2018; 33: 1184-8.
[21]
Bass M, Page RL II, Kiser TH, et al. Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. J Card Fail 2019; 25(8): S26-7.
[http://dx.doi.org/10.1016/j.cardfail.2019.07.073]
[22]
Robinson AA, Trankle CR, Eubanks G, et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol 2020; 5(6): 685-92.
[http://dx.doi.org/10.1001/jamacardio.2020.0652] [PMID: 32320043]
[23]
Weinsaft JW, Kim J, Medicherla CB, et al. Echocardiographic algorithm for post-myocardial infarction LV thrombus: A gatekeeper for thrombus evaluation by delayed enhancement CMR. JACC Cardiovasc Imaging 2016; 9(5): 505-15.
[http://dx.doi.org/10.1016/j.jcmg.2015.06.017] [PMID: 26476503]
[24]
Delewi R, Zijlstra F, Piek JJ. Left ventricular thrombus formation after acute myocardial infarction. Heart 2012; 98(23): 1743-9.
[http://dx.doi.org/10.1136/heartjnl-2012-301962] [PMID: 23151669]
[25]
Chiarella F, Santoro E, Domenicucci S, Maggioni A, Vecchio C. Predischarge two-dimensional echocardiographic evaluation of left ventricular thrombosis after acute myocardial infarction in the GISSI-3 study. Am J Cardiol 1998; 81(7): 822-7.
[http://dx.doi.org/10.1016/S0002-9149(98)00003-4] [PMID: 9555769]
[26]
Bulluck H, Chan MHH, Paradies V, et al. Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A meta-analysis. J Cardiovasc Magn Reson 2018; 20(1): 72.
[http://dx.doi.org/10.1186/s12968-018-0494-3] [PMID: 30404623]
[27]
Pöss J, Desch S, Eitel C, de Waha S, Thiele H, Eitel I. Left ventricular thrombus formation after st-segment-elevation myocardial infarction: Insights from a cardiac magnetic resonance multicenter study. Circ Cardiovasc Imaging 2015; 8(10): e003417.
[http://dx.doi.org/10.1161/CIRCIMAGING.115.003417] [PMID: 26481162]
[28]
Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. Executive summary: Antithrombotic therapy and prevention of thrombosis. Chest 2012; 141: 7s-47s.
[29]
Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42(5): 373-498.
[http://dx.doi.org/10.1093/eurheartj/ehaa612] [PMID: 32860505]
[30]
Stratton JR, Resnick AD. Increased embolic risk in patients with left ventricular thrombi. Circulation 1987; 75(5): 1004-11.
[http://dx.doi.org/10.1161/01.CIR.75.5.1004] [PMID: 3568301]
[31]
Oh JK, Park JH, Lee JH, Kim J, Seong IW. Shape and mobility of a left ventricular thrombus are predictors of thrombus resolution. Korean Circ J 2019; 49(9): 829-37.
[http://dx.doi.org/10.4070/kcj.2018.0346] [PMID: 31074225]
[32]
Keren A, Goldberg S, Gottlieb S, et al. Natural history of left ventricular thrombi: Their appearance and resolution in the posthospitalization period of acute myocardial infarction. J Am Coll Cardiol 1990; 15(4): 790-800.
[http://dx.doi.org/10.1016/0735-1097(90)90275-T] [PMID: 2307788]
[33]
Visser CA, Kan G, Meltzer RS, Lie KI, Durrer D. Long-term follow-up of left ventricular thrombus after acute myocardial infarction. A two-dimensional echocardiographic study in 96 patients. Chest 1984; 86(4): 532-6.
[http://dx.doi.org/10.1378/chest.86.4.532] [PMID: 6478891]
[34]
Ram P, Shah M, Sirinvaravong N, et al. Left ventricular thrombosis in acute anterior myocardial infarction: Evaluation of hospital mortality, thromboembolism, and bleeding. Clin Cardiol 2018; 41(10): 1289-96.
[http://dx.doi.org/10.1002/clc.23039] [PMID: 30084493]
[35]
Cannon CP, Bhatt DL, Oldgren J, et al. RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377(16): 1513-24.
[http://dx.doi.org/10.1056/NEJMoa1708454] [PMID: 28844193]
[36]
Lopes RD, Heizer G, Aronson R, et al. AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380(16): 1509-24.
[http://dx.doi.org/10.1056/NEJMoa1817083] [PMID: 30883055]
[37]
Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5(4): 886-8.
[http://dx.doi.org/10.1111/j.1538-7836.2007.02429.x] [PMID: 17388799]
[38]
Chen K, Williams S, Chan AK, Mondal TK. Thrombosis and embolism in pediatric cardiomyopathy. Blood Coagul Fibrinolysis 2013; 24(3): 221-30.
[http://dx.doi.org/10.1097/MBC.0b013e32835bfd85] [PMID: 23429248]
[39]
Abdo AS, Kemp R, Barham J, Geraci SA. Dilated cardiomyopathy and role of antithrombotic therapy. Am J Med Sci 2010; 339(6): 557-60.
[http://dx.doi.org/10.1097/MAJ.0b013e3181cf048a] [PMID: 20186041]
[40]
Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020; 42(5): 373-498.
[41]
Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375(25): 2423-34.
[http://dx.doi.org/10.1056/NEJMoa1611594] [PMID: 27959713]
[42]
Lattuca B, Bouziri N, Kerneis M, et al. ACTION Study Group.Antithrombotic therapy for patients with left ventricular mural thrombus. J Am Coll Cardiol 2020; 75(14): 1676-85.
[http://dx.doi.org/10.1016/j.jacc.2020.01.057] [PMID: 32273033]
[43]
van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993; 153(13): 1557-62.
[http://dx.doi.org/10.1001/archinte.1993.00410130073007] [PMID: 8323419]
[44]
He J, Ge H, Dong JX, et al. Rationale and design of a prospective multi-center randomized trial of early treatment by rivaroxaban versus warfarin in ST-segment elevation MYOcardial infarction with Left Ventricular Thrombus (EARLY-MYO-LVT trial). Ann Transl Med 2020; 8(6): 392.
[http://dx.doi.org/10.21037/atm.2020.02.117] [PMID: 32355836]

Rights & Permissions Print Cite
Article Metrics
58
1
World Health Day
© 2024 Bentham Science Publishers | Privacy Policy